Privalov M A, Sizenko A K
Lik Sprava. 2014 Nov(11):15-21.
Inflammatory bowel diseases (IBD) are chronic, recurrent disease associated with significant morbidity and disability rates and marked reduction of quality of life. The exact aetiology of these conditions is unknown, however, there is increasing data supporting the influence of gut microbiota in the pathogenesis of IBD. Despite of large number of actively exploring approaches to IBD treatment, some patients remain refractory to standard management or have significant adverse side effects. Given the probably role of the gastrointestinal microbiotain development of IBD, treatments that manipulate the microbiota have been investigated with varying degree of efficacy. Faecal microbiota transplantation (FMT) can be considered as alternative regimen for IBD management, but there is currently a lack of evidence supporting this approach in similar conditions. The comprehensive data are necessary to provide understandable and clear conclusion to guide current practice and future research.
炎症性肠病（IBD）是一种慢性复发性疾病，伴有显著的发病率和致残率，生活质量明显下降。这些疾病的确切病因尚不清楚，然而，越来越多的数据支持肠道微生物群在IBD发病机制中的影响。尽管有大量积极探索的IBD治疗方法，但一些患者对标准治疗仍有抵抗或有明显的不良副作用。鉴于胃肠道微生物群在IBD发生发展中可能发挥的作用，已对调节微生物群的治疗方法进行了不同程度疗效的研究。粪便微生物群移植（FMT）可被视为IBD治疗的替代方案，但目前缺乏在类似情况下支持该方法的证据。需要全面的数据来提供可理解且明确的结论，以指导当前的实践和未来的研究。
